CN106913487B - Compound mango leaf extract skin cream and preparation method thereof - Google Patents
Compound mango leaf extract skin cream and preparation method thereof Download PDFInfo
- Publication number
- CN106913487B CN106913487B CN201710277346.XA CN201710277346A CN106913487B CN 106913487 B CN106913487 B CN 106913487B CN 201710277346 A CN201710277346 A CN 201710277346A CN 106913487 B CN106913487 B CN 106913487B
- Authority
- CN
- China
- Prior art keywords
- mango leaf
- leaf extract
- parts
- skin
- mango
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000014826 Mangifera indica Nutrition 0.000 title claims abstract description 101
- 235000004936 Bromus mango Nutrition 0.000 title claims abstract description 100
- 235000009184 Spondias indica Nutrition 0.000 title claims abstract description 100
- 239000000284 extract Substances 0.000 title claims abstract description 64
- 239000002884 skin cream Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 150000001875 compounds Chemical class 0.000 title claims abstract description 18
- 240000007228 Mangifera indica Species 0.000 title description 6
- 241001093152 Mangifera Species 0.000 claims abstract description 94
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 claims abstract description 70
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 claims abstract description 35
- 229940043357 mangiferin Drugs 0.000 claims abstract description 35
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract description 28
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims abstract description 28
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960000271 arbutin Drugs 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 14
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 14
- 239000004408 titanium dioxide Substances 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 229960005196 titanium dioxide Drugs 0.000 claims abstract description 13
- 239000012463 white pigment Substances 0.000 claims abstract description 3
- 238000003756 stirring Methods 0.000 claims description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 27
- 238000001914 filtration Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 16
- 239000012071 phase Substances 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 16
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 claims description 9
- 230000001804 emulsifying effect Effects 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 229940057995 liquid paraffin Drugs 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- 229960000541 cetyl alcohol Drugs 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 235000010241 potassium sorbate Nutrition 0.000 claims description 7
- 239000004302 potassium sorbate Substances 0.000 claims description 7
- 229940069338 potassium sorbate Drugs 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 238000003808 methanol extraction Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 230000001376 precipitating effect Effects 0.000 claims description 5
- 239000008346 aqueous phase Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 235000010254 Jasminum officinale Nutrition 0.000 claims description 3
- 240000005385 Jasminum sambac Species 0.000 claims description 3
- 241000220317 Rosa Species 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 claims description 2
- 235000019082 Osmanthus Nutrition 0.000 claims description 2
- 241000333181 Osmanthus Species 0.000 claims description 2
- 235000010331 calcium propionate Nutrition 0.000 claims description 2
- 239000004330 calcium propionate Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 239000006071 cream Substances 0.000 abstract description 12
- 230000008961 swelling Effects 0.000 abstract description 8
- 208000003251 Pruritus Diseases 0.000 abstract description 7
- 206010003399 Arthropod bite Diseases 0.000 abstract description 6
- 206010017553 Furuncle Diseases 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000007803 itching Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 238000005461 lubrication Methods 0.000 abstract 1
- 239000002932 luster Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 15
- 239000000686 essence Substances 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940114930 potassium stearate Drugs 0.000 description 2
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 241000249058 Anthracothorax Species 0.000 description 1
- 235000008658 Artemisia capillaris Nutrition 0.000 description 1
- 241000092668 Artemisia capillaris Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000878006 Miscanthus sinensis Species 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000008845 cholagoga Substances 0.000 description 1
- 229940124571 cholagogue Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The invention belongs to the field of medical care and daily chemical products, and particularly relates to a compound mango leaf extract skin cream taking a mango leaf extract as a main active component and a preparation method thereof. The compound mango leaf extract skin cream has good prevention and treatment effects on skin itching and red swelling caused by skin furuncle and mosquito bite; the main active ingredients are mango leaf extract, arbutin, salicylic acid and titanium dioxide; the weight ratio of the mango leaf extract to the white pigment is 1-2 parts of mango leaf extract, 0.8-1.2 parts of arbutin, 0.8-1.2 parts of salicylic acid and 0.8-1.2 parts of titanium dioxide; the mangiferin content in the mango leaf extract is 60-70%. The mangiferin, arbutin, salicylic acid and titanium dioxide are matched with corresponding auxiliary materials to prepare cream, the cream can be quickly melted and disappeared after being smeared on skin, the skin has lubrication, moistening and luster feeling, and the cream has obvious effects of relieving itching, diminishing inflammation and promoting skin recovery aiming at skin pruritus caused by skin furuncle and mosquito bite.
Description
Technical Field
The invention belongs to the field of medical care and daily chemical products, and particularly relates to a compound mango leaf extract skin cream taking a mango leaf extract as a main active component and a preparation method thereof.
Background
Mango (Mangifera indica L.) is a common tropical fruit in southern regions of China. The mango planting area in the Panxi region in Sichuan is more than 30 ten thousand mu, the mango planting area has the characteristics of high yield and good quality, the mango planting area occupies the domestic late-maturing mango market, and the mango industry becomes the leading industry of local agriculture. Long-term test and analysis of the inventor show that the content of mangiferin (mangiferin) in mango leaves in the Panxi region is as high as 2-8%, which is much higher than that of other plants such as rhizoma anemarrhenae and the like, and is also much higher than that of mangiferin in mango leaves in other production regions in China.
Mangiferin, also known as guan Zhi Ning, pale gray yellow needle crystal (50% ethanol), has good curative effect in treating chronic bronchitis, is the main effective component of Tibetan capillary artemisia for treating hepatitis, and is the anti-virus active component in rhizome of rhizoma anemarrhenae. Modern medical research has proved that mangiferin also has the pharmacological actions of antioxidation, anti-inflammation, bacteriostasis, radiation resistance, preventing and treating skin aging, reducing blood sugar, reducing uric acid, anti-tumor, immunoregulation, cholagogue, inhibiting central nervous system, anti-inflammation, anti-herpes simplex virus HSV-2, relieving sacral radiculopathy caused by HSV-2 virus, and the like. In pharmacopoeia of China and quality standards of various traditional Chinese medicinal materials and Chinese patent medicines, the content of mangiferin is often used as a quality control index. The raw materials of the novel health care products or the medicines which are developed by taking mangiferin as a main component at present are mostly pure mangiferin products and are generally oral preparations. Because mangiferin has extremely low bioavailability to human bodies, the clinical trial effect of the oral preparation products is not ideal. References are as follows: [1] li Y J, Sui Y J, Dai YH, et a1.LC determination and pharmacologics determination of mangiferin in plantations and tissues [ J ]. Chromatographasia, 2008, 67(11-l 2): 957-; [2] research on in vitro metabolic transformation of mangiferin by human intestinal flora [ J ] research on mangiferin metabolism by chinese traditional medicine, journal of pith of Tantan treasure, Deng Jia, etc. [ 2011, 36 (4): 443-445.
the inventor of the invention develops a new method, and prepares a compound external preparation by taking a mango leaf extract (with the mangiferin content of 60-70%) as a main active ingredient, so that the defect of low bioavailability of the mangiferin for oral administration can be overcome, the drug effect can be fully exerted, mango leaf resources in mango planting fields can be fully utilized, the production cost of products is reduced, and the economic benefit of the mango industry is improved.
Disclosure of Invention
The invention aims to provide a compound mango leaf extract skin cream taking a mango leaf extract as a main raw material and a preparation method thereof. The skin cream has good prevention and treatment effects on skin itching and red swelling caused by skin furuncle and mosquito bite.
The main active ingredients of the compound mango leaf extract skin cream are mango leaf extract, arbutin, salicylic acid and titanium dioxide; the weight ratio of the mango leaf extract to the white pigment is 1-2 parts of mango leaf extract, 0.8-1.2 parts of arbutin, 0.8-1.2 parts of salicylic acid and 0.8-1.2 parts of titanium dioxide; the mangiferin content in the mango leaf extract is 60-70%.
In the compound mango leaf extract skin cream, the active component mangiferin has strong anti-inflammatory and antioxidant effects and is a core functional component; arbutin can cooperate with mangiferin to play the roles of resisting inflammation and oxidation, and also has the effects of whitening and removing freckles; salicylic acid is a traditional external anti-inflammatory drug and can enhance the anti-inflammatory effect of mangiferin; the three components jointly become the active components of the product; the titanium dioxide can cover the yellow color of mangiferin, and can generate a certain sunscreen effect on skin due to low ultraviolet transmittance.
Furthermore, on the basis of the main active ingredients of the skin cream, conventional auxiliary materials are added to prepare the external cream. Particularly, because the mango leaf extract has poor water solubility and lipid solubility and certain color, and the physical and appearance properties of the skin-care cream prepared by the conventional cream preparation method hardly meet the use requirements of products, the inventor especially develops the specific auxiliary material combination to play the effect of the active ingredient of the invention and meets the appearance property requirements of the products when in use.
In order to improve the water solubility and the fat solubility of mangiferin, the invention adopts a cream formulation, and the weight ratio is as follows:
1) the main active ingredients are as follows: 1-2 parts of mango leaf extract, 0.8-1.2 parts of arbutin, 0.8-1.2 parts of salicylic acid and 0.8-1.2 parts of titanium dioxide; the mangiferin content in the mango leaf extract is 60-70%.
2) Auxiliary materials: 4-6 parts of stearic acid, 0.8-1.2 parts of glycerin monostearate, 3-5 parts of butyl stearate, 1-3 parts of cetyl alcohol, 6-10 parts of glycerol, 0.8-1.2 parts of liquid paraffin, 0.2-0.3 part of potassium hydroxide, 0.4 part of preservative and 40-50 parts of distilled water or deionized water.
Furthermore, essence can be added into the auxiliary materials, and the adding amount of the essence is 0.1-0.3 part by weight for increasing aroma and seasoning.
Preferably, the essence can adopt common flavoring essences such as jasmine essence, rose essence, osmanthus essence and the like.
Preferably, sorbic acid, potassium sorbate and calcium propionate are used as the preservative, and potassium sorbate is preferably used.
The skin cream of the invention adopts stearic acid and potassium hydroxide as auxiliary materials, so that potassium stearate is produced through reaction, and the potassium stearate and the components such as glycerin monostearate, butyl stearate, cetyl alcohol and the like play a good emulsifying role together, so that the product has uniform and smooth texture. The glycerol is used as a water retention agent and a lubricant; the liquid paraffin plays a role in solidifying in the product, so that the product is more stable in properties, and has a certain barrier effect and a certain lubricating effect on skin; the potassium sorbate is a common preservative for cosmetics, and the safety and the using dosage are verified for a long time. Repeated tests prove that the skin cream with ideal properties can be obtained by adopting the components and the corresponding proportion because the mangiferin has poor water solubility and lipid solubility.
The preparation method of the skin cream provided by the invention comprises the following steps of weighing the main active ingredients and the auxiliary materials according to the weight ratio:
A. preparation of a two-phase solution:
1) mixing stearic acid, glycerol, glyceryl monostearate, butyl stearate, cetyl alcohol and liquid paraffin, stirring and heating to 90-100 ℃, and maintaining for 20-40 min to obtain an oil phase solution;
2) mixing and dissolving water and potassium hydroxide, heating to 90-100 ℃ while stirring, and maintaining for 10-15 min to obtain an aqueous phase solution;
B. stirring and emulsifying: and C, controlling the temperature of the oil phase solution obtained in the step A to be 85-95 ℃, then adding the water phase solution obtained in the step A, stirring for 10-20min, then sequentially adding the mango leaf extract, arbutin, salicylic acid and titanium dioxide, stirring uniformly, and gradually reducing the temperature to 55-60 ℃ to obtain a uniform paste.
C. Standing, cooling, and packaging.
The inventor tests prove that the adding sequence of the materials cannot be reversed, otherwise, the finally obtained product cannot easily meet the requirement of satisfactory appearance properties. The product disclosed by the invention is prepared into cream by matching mangiferin, arbutin, salicylic acid and titanium dioxide with corresponding auxiliary materials, the cream can be quickly melted and disappeared after being smeared on skin, the skin has lubrication, moistening and luster feeling, and the cream has obvious effects of relieving itching, diminishing inflammation and promoting skin recovery aiming at skin pruritus caused by skin furuncle and mosquito bite.
Detailed Description
The advantageous effects of the present invention are illustrated by the following preparation examples of the present invention.
The mango leaf extract with the mangiferin content of 60-70% is prepared by a method for extracting and separating the mangiferin from the mango leaves with Chinese patent application number 201720057903.7, and specifically the mango leaf extract with the mangiferin content of 60-70% is obtained by extraction and separation from the mango leaves, and comprises the following steps:
A. preparing raw materials: drying mango leaves serving as a raw material, crushing, and sieving with a 20-40-mesh sieve to obtain mango leaf powder;
B. ester extraction and impurity removal: weighing mango leaf powder, adding 2-4L ethyl acetate into each kilogram of mango leaf powder, sealing and soaking for more than or equal to 4h, shaking at room temperature for more than or equal to 10min, and filtering; repeatedly extracting for 3-5 times until the green color of the extractive solution is almost disappeared to obtain mango leaf residue;
C. methanol extraction: taking the mango leaf residue extracted in the step B, adding 2-4L of methanol into each kilogram of mango leaf residue, sealing and soaking for more than or equal to 4 hours at the temperature of 30-40 ℃, stirring and extracting for 0.5-1 hour at the temperature of 50-60 ℃, filtering while hot, repeatedly extracting for 4-6 times, combining extracting solutions, precipitating at room temperature for more than or equal to 8 hours, and filtering to obtain a filtrate;
D. concentration and washing: concentrating the filtrate obtained in the step C into a thick extract, adding 2-4L of methanol into each kilogram of extract, stirring and washing at 50-60 ℃, cooling, filtering, and repeatedly washing for 3-5 times until filter residues are yellow-white particles; drying the filter residue to obtain a mangiferin crude product with the purity of 60-70%.
Wherein, fresh mango leaves are adopted as the mango leaves in the step A; in particular, fresh mango tender leaves are adopted as the mango leaves in the step A. However, in view of the collection of the raw materials, young leaves of mango, old leaves at the base of the shoot, and a mixture thereof are generally used. This is because the inventors found: the mango leaf content in mango leaves of different varieties and old tender degrees is greatly different, for example, the content of Kate, Haiton, Jilu and other varieties with large planting areas is generally 2-4%, the content of traditional old varieties such as Miscanthus sinensis and the like can be as high as 6-8%, and the content of tip tender leaves of the same variety is far higher than that of old leaves at the base of branches. Therefore, the raw materials used in the extraction method mainly comprise tender leaves of various mangos, old leaves at the base of branches and mixtures thereof, and fresh mango leaves can be collected as mixed raw materials during flower thinning and fruit thinning or during pruning after mango harvesting.
Preferably, the drying in the step A is natural drying or drying at 45-65 ℃ until the moisture content is less than 8%.
Preferably, the room temperature precipitation in the step C is filtered for more than or equal to 8 hours, and a filter screen with more than or equal to 200 meshes is adopted for fine filtration.
Preferably, the filtrate obtained in the step D is concentrated by vacuum rotary evaporation at the temperature of 5-65 ℃.
Preferably, the step D is carried out for stirring and washing for 10-20min at 50-60 ℃.
Preferably, the filtering in the step D adopts a filter screen with the mesh size of more than or equal to 200.
Preferably, the drying in the step D is drying at 50-60 ℃.
Mango leaf extract example 1
A. Preparing raw materials: fresh mango leaves are taken as raw materials, naturally dried in the sun or dried at 50 ℃, crushed and sieved by a 20-mesh sieve.
B. Ester extraction and impurity removal: weighing 1000g of mango leaf powder, adding 3L of ethyl acetate, sealing and soaking for 5h, shaking and extracting at room temperature for 15min, and filtering; the extraction is repeated for 4 times, and the green color of the extractive solution basically disappears.
C. Methanol extraction: and D, adding 2.5L of methanol into the residue extracted in the step B, soaking for 5h at 30 ℃ in a sealed manner, stirring and extracting for 0.5h at 55 ℃, filtering while hot, repeatedly extracting for 5 times, combining the extracting solutions, precipitating for 9h at room temperature, and finely filtering by using a 200-mesh filter screen.
D. Concentration and washing: and C, carrying out vacuum rotary evaporation and concentration on the filtrate obtained in the step C at 50 ℃ to obtain about 50g of concentrated extract, adding 150mL of methanol, stirring and washing for 10min at 55 ℃, cooling, filtering by using a 200-mesh filter screen, and repeatedly washing for 4 times, wherein filter residues are yellow-white particles. Drying the filter residue at 55 ℃ to obtain a mangiferin crude product (namely the mango leaf extract used by the invention) with the purity of 62.5 percent, wherein the yield is about 84.5 percent.
Mango leaf extract example 2
A. Preparing raw materials: fresh mango leaves are used as raw materials, naturally dried in the sun, crushed and sieved by a 30-mesh sieve.
B. Ester extraction and impurity removal: weighing 1000g of mango leaf powder, adding 4L of ethyl acetate, sealing and soaking for 4h, shaking at room temperature for 10min, and filtering; the extraction is repeated for 3 times, and the green color of the extractive solution basically disappears.
C. Methanol extraction: and D, adding 4L of methanol into the residue extracted in the step B, hermetically soaking at 40 ℃ for 4h, stirring and extracting at 60 ℃ for 0.5h, filtering while hot, repeatedly extracting for 4 times, combining the extracting solutions, precipitating at room temperature for 10h, and finely filtering by using a 200-mesh filter screen.
D. Concentration and washing: and C, carrying out vacuum rotary evaporation on the filtrate obtained in the step C at 65 ℃ to concentrate the filtrate into a thick extract, adding 200mL of methanol, stirring and washing at 50 ℃ for 20min, cooling, filtering by using a 200-mesh filter screen, repeatedly washing for 5 times, and enabling filter residues to be yellow-white particles. Drying the filter residue at 50 ℃ to obtain 43.4g of mangiferin crude product with the purity of 67.6% (namely the mango leaf extract used by the invention).
Mango leaf extract example 3
A. Preparing raw materials: fresh mango leaves are taken as raw materials, dried at 65 ℃, crushed and sieved by a 40-mesh sieve.
B. Ester extraction and impurity removal: weighing 1000g of mango leaf powder, adding 2L of ethyl acetate, sealing and soaking for 6h, shaking at room temperature for 20min, and filtering; the extraction is repeated for 5 times, and the green color of the extractive solution basically disappears.
C. Methanol extraction: and D, adding 2L of methanol into the residue extracted in the step B, soaking for 6h at 30 ℃ in a sealed manner, stirring and extracting for 1h at 60 ℃, filtering while hot, repeatedly extracting for 6 times, combining the extracting solutions, precipitating for 12h at room temperature, and finely filtering by using a 200-mesh filter screen.
D. Concentration and washing: and C, carrying out vacuum rotary evaporation on the filtrate obtained in the step C at 65 ℃ to concentrate the filtrate into a thick extract, adding 130mL of methanol, stirring and washing at 50 ℃ for 20min, cooling, filtering by using a 200-mesh filter screen, repeatedly washing for 5 times, and enabling filter residues to be yellow-white particles. Drying the filter residue at 60 ℃ to obtain 48.2g of a mangiferin crude product with the purity of 66.5% (namely the mango leaf extract used by the invention).
The preparation example of the skin cream is as follows, and the mangiferin content of the mango leaf extract is 60-70%.
Example 1
1. The raw material formula is as follows:
50g of stearic acid, 10g of glyceryl monostearate, 40g of butyl stearate, 20g of hexadecanol, 80g of glycerol, 10g of liquid paraffin, 2.5g of potassium hydroxide, 10g of arbutin, 15g of mango leaf extract, 10g of titanium dioxide, 10g of salicylic acid, 5g of potassium sorbate, 2g of jasmine essence, 400g of deionized water
2. The preparation method comprises the following steps: the method comprises the following steps:
A. preparation of a two-phase solution: according to the amount in the formula, materials such as glycerol, glyceryl monostearate, butyl stearate, cetyl alcohol, liquid paraffin and the like are firstly put into a stainless steel heating pot with a steam jacket, stirred and heated to 95 ℃ for 30min, and an oil phase solution is obtained. Then putting the water and the potassium hydroxide in the formula into another stainless steel heating pot with a steam jacket, stirring and heating to 95 ℃, and maintaining for 12min to obtain an aqueous phase solution.
B. Stirring and emulsifying: placing the prepared oil phase solution into an emulsifying and stirring pot, heating and stirring, controlling the temperature in the pot to be stable at 90 ℃, then placing the water phase solution into the pot, stirring for 15min, then adding all other components in the formula into the pot, stirring uniformly, and gradually reducing the temperature in the pot to 60 ℃ to obtain the uniform paste.
C. Standing and cooling: pressing the uniform paste in the emulsifying stirring pot, standing, and cooling the paste to 35 ℃.
D. Filling: and (4) putting the cooled paste into an automatic filling machine, subpackaging into skin care product packaging containers, and sealing to obtain the product.
Example 2
1. The raw material formula is as follows:
40g of stearic acid, 8g of glyceryl monostearate, 30g of butyl stearate, 10g of hexadecanol, 60g of glycerol, 8g of liquid paraffin, 2g of potassium hydroxide, 8g of arbutin, 10g of mango leaf extract, 8g of titanium dioxide, 8g of salicylic acid, 4g of potassium sorbate, 1g of rose essence and 300g of distilled water.
2. The preparation method comprises the following steps: the method comprises the following steps:
A. preparation of a two-phase solution: according to the amount in the formula, materials such as glycerol, glyceryl monostearate, butyl stearate, cetyl alcohol, liquid paraffin and the like are firstly put into a stainless steel heating pot with a steam jacket, and are stirred and heated to 90 ℃ for 20min to obtain an oil phase solution. Then putting the water and the potassium hydroxide in the formula into another stainless steel heating pot with a steam jacket, stirring and heating to 90 ℃, and maintaining for 10min to obtain an aqueous phase solution.
B. Stirring and emulsifying: putting the prepared oil phase solution into an emulsifying and stirring pot, heating and stirring, controlling the temperature in the pot to be 85 ℃, putting the water phase solution into the pot, stirring for 20min, adding all other components in the formula into the pot, stirring uniformly, and gradually reducing the temperature in the pot to 55 ℃ to obtain a uniform paste.
C. Standing and cooling: pressing the uniform paste in the emulsifying stirring pot, standing, and cooling the paste to 30 ℃.
D. Filling: and (4) putting the cooled paste into an automatic filling machine, subpackaging into skin care product packaging containers, and sealing to obtain the product.
The quality characteristics of the ointment products prepared in the above examples 1-2 are shown in Table 1.
TABLE 1 appearance and quality attributes of skin cream products of the present invention
Aiming at the skin cream, the inventor carries out comparative analysis on the anti-inflammatory effect of the skin cream by using the inhibition rate of the skin cream on inflammation as an index through a dimethylbenzene induced mouse ear swelling test. Three different creams were made according to the invention example 1 as control and test group respectively: a (negative control group): cream is prepared according to the example 1 by adding only auxiliary materials without adding active ingredients; b (test group without mango leaf extract): a cream was prepared according to example 1 by adding ingredients except the mango leaf extract; c (mango leaf extract added test group): a cream was prepared according to example 1. The test is divided into three different groups, after the auricle on one side of the mouse is smeared with xylene to cause swelling, the three creams are smeared on the swelling part of the auricle of the mouse respectively, and the swelling degree and the inflammation inhibition rate of the auricle of each group of the mouse are measured after 2 hours, and the result is shown in a table 2. As can be seen from table 2, the control group without the addition of active ingredient had no anti-inflammatory effect, and both of the two test groups with the addition of active ingredient had anti-inflammatory effects, but the anti-inflammatory effects between the two test groups with the addition of mango leaf extract and without the addition of mango leaf extract were significantly different, and the anti-inflammatory effect of the former was 74.9% higher than that of the latter.
TABLE 2 investigation of the clinical trial effect of the skin cream product of the present invention
Aiming at the skin cream, the inventor carries out clinical trial effect observation on patients with skin itch and red swelling caused by skin furuncle and mosquito bite, and carries out statistical analysis on the effective rate and the effective time, and the result is shown in table 3. Therefore, the total effective rate of the product of the invention on skin inflammation such as skin furuncle, red swelling caused by mosquito bite, pruritus and the like is more than 71%, and the product has good effect on protecting skin.
TABLE 3 investigation of the clinical trial effect of the skin cream product of the present invention
| Type of patient | Number of patients | Is effective | Invalidation | Time of onset (h) | Effective rate (%) |
| Skin furuncle | 32 | 23 | 9 | 8～24 | 71.8 |
| Skin itching and red swelling caused by mosquito bites | 35 | 31 | 4 | 0.2-2 | 88.6 |
Claims (9)
1. The compound mango leaf extract skin cream is characterized in that: the main active ingredients are mango leaf extract, arbutin, salicylic acid and titanium dioxide; the weight ratio of the mango leaf extract to the white pigment is 1-2 parts of mango leaf extract, 0.8-1.2 parts of arbutin, 0.8-1.2 parts of salicylic acid and 0.8-1.2 parts of titanium dioxide; wherein, the content of mangiferin in the mango leaf extract is 60-70%;
the preparation method of the mango leaf extract with the mangiferin content of 60-70% comprises the following steps:
A. preparing raw materials: drying mango leaves serving as a raw material, crushing, and sieving with a 20-40-mesh sieve to obtain mango leaf powder;
B. ester extraction and impurity removal: weighing mango leaf powder, adding 2-4L ethyl acetate into each kilogram of mango leaf powder, sealing and soaking for more than or equal to 4h, shaking at room temperature for more than or equal to 10min, and filtering; repeatedly extracting for 3-5 times until the green color of the extractive solution disappears to obtain mango leaf residue;
C. methanol extraction: taking the mango leaf residue extracted in the step B, adding 2-4L of methanol into each kilogram of mango leaf residue, sealing and soaking for more than or equal to 4 hours at the temperature of 30-40 ℃, stirring and extracting for 0.5-1 hour at the temperature of 50-60 ℃, filtering while hot, repeatedly extracting for 4-6 times, combining extracting solutions, precipitating at room temperature for more than or equal to 8 hours, and filtering to obtain a filtrate;
D. concentration and washing: concentrating the filtrate obtained in the step C into a thick extract, adding 2-4L of methanol into each kilogram of extract, stirring and washing at 50-60 ℃, cooling, filtering, and repeatedly washing for 3-5 times until filter residues are yellow-white particles; drying the filter residue to obtain a mangiferin crude product with the purity of 60-70%, namely the mango leaf extract.
2. The compound mango leaf extract skin cream as claimed in claim 1, characterized in that: based on the main active ingredients, conventional auxiliary materials are added to prepare the skin cream.
3. The compound mango leaf extract skin cream as claimed in claim 1, characterized in that: the weight ratio is as follows:
the main active ingredients are as follows: 1-2 parts of mango leaf extract, 0.8-1.2 parts of arbutin, 0.8-1.2 parts of salicylic acid and 0.8-1.2 parts of titanium dioxide;
auxiliary materials: 4-6 parts of stearic acid, 0.8-1.2 parts of glycerin monostearate, 3-5 parts of butyl stearate, 1-3 parts of cetyl alcohol, 6-10 parts of glycerol, 0.8-1.2 parts of liquid paraffin, 0.2-0.3 part of potassium hydroxide, 0.4 part of preservative and 40-50 parts of distilled water or deionized water.
4. The compound mango leaf extract skin cream as claimed in claim 3, characterized in that: the auxiliary materials also comprise essence.
5. The compound mango leaf extract skin cream as claimed in claim 4, characterized in that: the addition amount of the essence is 0.1-0.3 part by weight of the essence.
6. The compound mango leaf extract skin cream as claimed in claim 4, characterized in that: the essence adopts jasmine essence, rose essence or osmanthus essence.
7. The compound mango leaf extract skin cream as claimed in claim 3, characterized in that: the preservative adopts sorbic acid, potassium sorbate or calcium propionate.
8. The compound mango leaf extract skin cream as claimed in claim 7, characterized in that: the preservative adopts potassium sorbate.
9. The preparation method of the compound mango leaf extract skin cream as claimed in any one of claims 1 to 8, which is characterized in that: the preparation method comprises the following steps:
A. preparation of a two-phase solution:
1) mixing stearic acid, glycerol, glyceryl monostearate, butyl stearate, cetyl alcohol and liquid paraffin, heating to 90-100 ℃ while stirring, and maintaining for 20-40 min to obtain an oil phase solution;
2) mixing water and potassium hydroxide, heating to 90-100 ℃ while stirring, and maintaining for 10-15 min to obtain an aqueous phase solution;
B. stirring and emulsifying: controlling the temperature of the oil phase solution obtained in the step A to be 85-95 ℃, then adding the water phase solution obtained in the step A, stirring for 10-20min, then adding the mango leaf extract, arbutin, salicylic acid and titanium dioxide, stirring uniformly, and gradually reducing the temperature to 55-60 ℃ to obtain a uniform paste;
C. standing, cooling, and packaging.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710277346.XA CN106913487B (en) | 2017-04-25 | 2017-04-25 | Compound mango leaf extract skin cream and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710277346.XA CN106913487B (en) | 2017-04-25 | 2017-04-25 | Compound mango leaf extract skin cream and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106913487A CN106913487A (en) | 2017-07-04 |
| CN106913487B true CN106913487B (en) | 2020-10-16 |
Family
ID=59567605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710277346.XA Expired - Fee Related CN106913487B (en) | 2017-04-25 | 2017-04-25 | Compound mango leaf extract skin cream and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106913487B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111012705A (en) * | 2019-12-18 | 2020-04-17 | 广州市巧美化妆品有限公司 | Extraction process of kapok leaf extract and essence cream thereof |
| GB202017114D0 (en) * | 2020-10-28 | 2020-12-09 | Givaudan Sa | Improvements in or relating to extracts |
| CN116549359B (en) * | 2023-06-16 | 2024-02-06 | 诺德溯源(广州)生物科技有限公司 | Acne-removing composition for optimizing skin grease quality and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655381A (en) * | 2013-12-27 | 2014-03-26 | 茂名职业技术学院 | Method for extracting sun shielding ingredient from mango or orange leaves |
| CN103768112A (en) * | 2012-10-26 | 2014-05-07 | 昆明制药集团股份有限公司 | Mango leaf extract and application thereof |
| CN106176536A (en) * | 2016-08-24 | 2016-12-07 | 李斌 | A kind of whitening beauty treatment emulsion |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008079898A1 (en) * | 2006-12-20 | 2008-07-03 | Pharmwest, Inc. | Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions |
-
2017
- 2017-04-25 CN CN201710277346.XA patent/CN106913487B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103768112A (en) * | 2012-10-26 | 2014-05-07 | 昆明制药集团股份有限公司 | Mango leaf extract and application thereof |
| CN103655381A (en) * | 2013-12-27 | 2014-03-26 | 茂名职业技术学院 | Method for extracting sun shielding ingredient from mango or orange leaves |
| CN106176536A (en) * | 2016-08-24 | 2016-12-07 | 李斌 | A kind of whitening beauty treatment emulsion |
Non-Patent Citations (1)
| Title |
|---|
| 芒果不同部位化学成分和药理作用的研究近况;陈仪新等;《广西中医药大学学报》;20151231;第18卷(第2期);102-105 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106913487A (en) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106913487B (en) | Compound mango leaf extract skin cream and preparation method thereof | |
| US10172900B2 (en) | Composition with improved bioavailabilty of saponin and method for improving the bioavailability of saponin | |
| KR101050472B1 (en) | Multifunctional beauty soap and its manufacturing method | |
| DE112012001540T5 (en) | Drug compound for the control of blood glucose, blood lipids and weight | |
| CN107028829B (en) | Compound mango leaf extract anti-inflammatory health-care toothpaste and preparation method thereof | |
| CN106038415A (en) | Cosmetic composition containing gynura formosana extract | |
| CN101579112B (en) | Throat relieving drink and preparation method thereof | |
| CN100506238C (en) | Composition of bitter melon polysaccharide for reducing blood sugar, and preparation method | |
| CN101982184B (en) | Preparation method of taraxacum extract | |
| CN107823026A (en) | A kind of fermentation and its is preparing the application of skin whitening, moisturizing skin care item at compound | |
| CN106581115B (en) | Composition containing yuankanin and ginseng and application thereof | |
| CN116999361A (en) | Anti-inflammatory acne-removing mask essence, preparation method and application thereof, and anti-inflammatory acne-removing mask | |
| US5262161A (en) | Stevia extract-containing medicine | |
| CN108785358A (en) | A kind of preparation method of Honegsukle flower P.E | |
| CN108619017A (en) | A kind of Tianshan Mountains snow chrysanthemum skin care compositions and its application | |
| KR100546735B1 (en) | Skin Whitening Composition | |
| CN108175735A (en) | A kind of moist reparation eye cream of the extract containing American cockroach | |
| CN107372967A (en) | A kind of tea-drinking for improving blood stasis constitution | |
| KR101131719B1 (en) | Pulsatilla koreana extracts compositions for treating or preventing inflammatory diseases | |
| CN111773149A (en) | Skin care composition and preparation method thereof | |
| CN109602781A (en) | A kind of preparation method of Honegsukle flower P.E | |
| KR20190025863A (en) | Cosmetic or phamaceutical composition comprising herb extract and method for preparing the same | |
| CN104940428B (en) | Hypoglycemic composition containing wolfberry fruits and application thereof | |
| KR20200109592A (en) | The composition with antioxidant and anti-inflammatory activity containing Lycium chinense leaf extract of Chengyang | |
| CN103719502B (en) | A kind of metapanax of araliaceae prepares the method for tealeaves |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221109 Address after: 230051 C802, Qingwang Science Park, Baohe District, Hefei, Anhui Patentee after: Hefei little hedgehog Information Technology Co.,Ltd. Address before: 617000 Airport Road, East District, Panzhihua, Sichuan Province, No. 10 Patentee before: PANZHIHUA University Patentee before: PANZHIHUA SANBOSHI TECHNOLOGY CO.,LTD. Effective date of registration: 20221109 Address after: 570100 Guilin Ocean Technology Business Incubator ZD-201, Xingyang Avenue, Jiangdong New District, Meilan District, Haikou, Hainan Patentee after: Hainan V Shiqichang Biotechnology Co.,Ltd. Address before: 230051 C802, Qingwang Science Park, Baohe District, Hefei, Anhui Patentee before: Hefei little hedgehog Information Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201016 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |